There is very little data on long-term outcomes from pediatric patients with inflammatory bowel disease treated with anti-TNF biosimilars.

An analysis of the UK Biobank suggests individuals with celiac disease had an incidence rate of 9.0 CVD cases per 1000 person years compared with 7.4 per 1000 person years in people with no celiac disease.

Adalimumab-atto will be used to treat several inflammatory diseases, including rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis.

The FDA announced that Banana Boat Hair & Scalp Sunscreen was being recalled voluntarily by its company due to risk of benzene exposure to consumers.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, look to the future at what is upcoming in the treatment pipeline for plaque psoriasis treatment.

Dermatology experts discuss looking ahead at clinical trial metrics and how to make different outcomes more highlighted to overcome challenges in plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss treating older populations and skin of color patients with plaque psoriasis.

Our latest cardiology case report features a woman in her 70s presenting to the hospital with 5 days of radiating chest pain. Check out the ECG and determine the correct diagnosis!

New research into atopic dermatitis treatment indicated that topical JAK inhibitors were safe and effective, although more research is needed regarding adverse effects.

Risankizumab is the latest biologic approved by the FDA and the first-ever IL-23A targeted therapy approved for the treatment of patients with Crohn's disease.

The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.

In new research, an association between food allergies and atopic dermatitis was highlighted, suggesting the need for further research.

The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease.

"All forms of arthritis can make life difficult for people because of the pain, swelling, or stiffness in a joint or joints, and because of difficulties in getting about," investigators explained.

Dr. Ian Flinn explains that as a Bruton's tyrosine kinase (BTK) therapy, zanubrutinib provides an option with reduced adverse events compared with chemotherapy treatments like venetoclax.

New data from the AHA 2023 Statistical Update suggest more people died from cardiovascular-related causes in 2020 than in any year since 2003.

“Our primary motivation was to help develop treatments for people with osteoarthritis that would slow or prevent the disease and be more than painkillers- actually affect the disease process itself,” Virginia Kraus, MD, explains.

The specific mechanisms involved in associations between air pollution and respiratory illness without viral infection are not understood, especially compared with those of respiratory viruses and asthma exacerbation.

The risk of diabetes was reduced by approximately 50% in both the vigorous and moderate aerobic exercise groups compared with the nonexercise group.

Crosbie presented results from a small pilot study testing a video game platform for patients with executive function deficits during the annual APSARD meeting.

A systematic review and meta-analysis of nearly 3 dozen published articles details the apparent increase in risk of cardiovascular disease and diabetes associated with a diagnosis of autism.

New research, comparable with that of the NAVIGATE trial, was conducted and showed strong results for the use of guselkumab for psoriasis patients.

The 2 strains identified were highly similar and exhibited differences of only 2 single-nucleotide polymorphisms.

In this episode of Diabetes Dialogue, ours hosts discuss the clearance of Tidepool Loop, what is unique about the app’s customizability and compatibility with other diabetes technologies, and other top points for people with diabetes and members of the diabetes care team to consider with the technology moving into the future.

In a recent study, DLE patients responded well to topical niacinamide 2% and 4% as adjuvant therapy, with strong results and few side effects.